Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Medicxi Ventures Management (Jersey) Ltd (CIK 1715579) reported $981.8M across 4 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: CNTA ($792.9M, 80.76%), NAMS ($85.6M, 8.72%), PHAT ($82.9M, 8.45%), AURA ($20.3M, 2.07%), RAPT ($0, 0.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | CNTA | CENTESSA PHARMACEUTICALS PLC | $792.9M | 80.76% | 20.0M | Hold |
| 2 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $85.6M | 8.72% | 2.7M | Trimmed |
| 3 | PHAT | PHATHOM PHARMACEUTICALS INC | $82.9M | 8.45% | 7.5M | Hold |
| 4 | AURA | AURA BIOSCIENCES INC | $20.3M | 2.07% | 3.0M | Hold |
| 5 | RAPT | RAPT THERAPEUTICS INC | $0 | 0.00% | 0 | Exited |
Source: SEC Form 13F filings · as of 2026-03-31